ABT - Abbott Laboratories

NYSE - NYSE Delayed Price. Currency in USD
83.16
-0.65 (-0.78%)
At close: 4:00PM EDT

84.35 +1.19 (1.43%)
Pre-Market: 8:32AM EDT

Stock chart is not supported by your current browser
Previous Close83.81
Open84.11
Bid84.50 x 900
Ask83.96 x 900
Day's Range82.90 - 84.24
52 Week Range62.87 - 85.99
Volume3,866,831
Avg. Volume5,249,708
Market Cap146.709B
Beta (3Y Monthly)0.87
PE Ratio (TTM)56.42
EPS (TTM)1.47
Earnings DateJul 17, 2019
Forward Dividend & Yield1.28 (1.54%)
Ex-Dividend Date2019-07-12
1y Target Est87.44
Trade prices are not sourced from all markets
  • MarketWatch36 minutes ago

    Abbott stock rises after earnings beat, full-year guidance boost

    Shares of Abbott Laboratories gained 0.8% in premarket trade Wednesday after the medical-device maker reported second-quarter earnings that topped Wall Street expectations and raised full-year guidance, though the company missed expectations for revenue. Profit for the latest quarter rose to $1.465 billion, or 56 cents a share, from $733 million, or 41 cents a share, from the year-earlier quarter. Adjusted EPS was 82 cents, topping the FactSet consensus of 80 cents. Revenue rose 2.7% to $7.979 billion from $7.767 billion a year ago. Analysts polled by FactSet had expected $7.997 billion in sales. Sales of the company's nutrition unit rose 0.9% to $1.875 billion, while the diagnostics sales rose 1.7% to $1.905 billion. Sales of the established pharmaceuticals business fell 1.8% to $1.108 billion, while sales of the medical devices unit rose 6.4% to $3.075 billion, boosted by strong sales of the company's FreeStyle Libre glucose monitoring system and MitraClip. Abbott raised its full-year EPS to between $3.21 and $3.27 from between $3.15 and $3.25. "Our sales growth accelerated and is sustainable," Abbott's Chief Executive Miles D. White said in a statement. "We have great momentum and are raising our guidance above the strong outlook we previously set for the year." Shares of Abbott have gained 15% so far this year through Tuesday, while the S&P 500 has gained 19.8%.

  • Abbott Earnings Narrowly Top; Health Care Giant Raises Guidance
    Investor's Business Daily45 minutes ago

    Abbott Earnings Narrowly Top; Health Care Giant Raises Guidance

    Abbott Laboratories earnings beat second-quarter earnings views. The health care giant raised full-year guidance. Abbott stock edged up early Wednesday.

  • PR Newswire1 hour ago

    Abbott Reports Second-Quarter 2019 Results

    - Accelerated and sustainable growth driven by strong performance across portfolio - Raising full-year guidance for organic sales growth to 7 to 8 percent - Double-digit EPS growth exceeded expectations; ...

  • ACCESSWIRE2 hours ago

    Abbott Laboratories to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 17, 2019 / Abbott Laboratories (NYSE: ABT ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 17, 2019 at 9:00 AM Eastern ...

  • TheStreet.com5 hours ago

    Abbott Laboratories Tops Q2 Profit Forecast, Boosts Guidance, As Libre Surges

    Abbott Laboratories posted stronger-than-expected second quarter earnings Wednesday, and boosted its full-year profit guidance, as sales of its FreeStyle Libre glucose monitoring system surged following FDA approval in 2017.

  • Investing.com5 hours ago

    Abbott Labs Earnings Beat, Revenue Misses In Q2

    Investing.com - Abbott Labs (NYSE:ABT) reported second quarter earnings that beat analysts' expectations on Wednesday and revenue that fell short of forecasts.

  • 5 Stocks with Spectacular Earnings Charts
    Zacks21 hours ago

    5 Stocks with Spectacular Earnings Charts

    These companies aren't just beating on earnings, their stocks are also on fire, hitting new 5-year highs.

  • Abbott MitraClip G4 Gets FDA Nod, Valve Repair Options Expand
    Zacksyesterday

    Abbott MitraClip G4 Gets FDA Nod, Valve Repair Options Expand

    The FDA approval for MitraClip G4 is expected to enhance Abbott's (ABT) cardiac treatment portfolio.

  • Reutersyesterday

    Abbott to hike production of lower-cost glucose monitors as diabetes soars

    Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters. Abbott executives said the increase in manufacturing capacity will begin in the second half of this year and make room for the expected U.S. launch of the FreeStyle Libre 2. Abbott's plans for Libre, its fastest-growing diabetes product, used by 1.5 million people worldwide, will be in focus when the company reports quarterly earnings on Wednesday.

  • Reutersyesterday

    FOCUS- Abbott to hike production of lower-cost glucose monitors as diabetes soars

    Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters. Abbott executives said the increase in manufacturing capacity will begin in the second half of this year and make room for the expected U.S. launch of the FreeStyle Libre 2. Abbott's plans for Libre, its fastest-growing diabetes product, used by 1.5 million people worldwide, will be in focus when the company reports quarterly earnings on Wednesday.

  • PR Newswire2 days ago

    Abbott Receives U.S. Approval of Next-Generation MitraClip®, Bringing New Enhancements to Abbott's Leading MitraClip Platform

    ABBOTT PARK, Ill., July 15, 2019 /PRNewswire/ -- Abbott (ABT) today announced the company has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip™ heart valve repair device to treat mitral regurgitation. The latest approval for the fourth-generation MitraClip device, MitraClip G4, puts new enhancements into the hands of physicians across the U.S. by delivering an expanded range of clip sizes, an alternative leaflet grasping feature and facilitation of procedure assessment in real time to offer doctors further options when treating mitral valve disease.

  • Will Abbott's (ABT) Q2 Earnings Gain From Overall Growth?
    Zacks2 days ago

    Will Abbott's (ABT) Q2 Earnings Gain From Overall Growth?

    Abbott's (ABT) consistent rise on a strong Diabetes Care business performance is seen over the last few quarters.

  • ABT or BIO: Which Stock Has Better Potential Right Now?
    Zacks2 days ago

    ABT or BIO: Which Stock Has Better Potential Right Now?

    Abbott (ABT) scores higher than Bio-Rad (BIO) in terms of valuation and one-year price performance.

  • MoneyShow2 days ago

    Abbott Laboratories ABT- 2019 Top Picks' Mid-Year Update

    Jim Woods, editor of Bullseye Stock Trader, chose Abbott Laboratories (ABT) as his top conservative investment idea for 2019. The stock has since risen 16%. Here's his latest update on the healthcare firm.

  • Morningstar4 days ago

    The Week Ahead: Earnings Season Heats Up

    We're watching earnings from several wide- and narrow-moat companies, plus retail sales and housing starts.

  • 4 Healthcare Stocks That Are Feeling Sick
    InvestorPlace5 days ago

    4 Healthcare Stocks That Are Feeling Sick

    While the broad U.S. equity market is pushing confidently to new all-time highs, healthcare stocks are lagging badly. The entire sector has come under pressure after President Donald Trump's effort to lower drug prices high a legal roadblock when a judge blocked a new requirement to list prices in commercials. The Trump Administration also reversed its plan to curb drug rebates for government healthcare plans.The pressure isn't slowing down, with the Health Care Select SPDR (NYSEARCA:XLV) cutting down out of a multi-week consolidation range to put an end to a three-month uptrend. This also marks a turnaround at resistance from the early December highs and sets up a decline back to the mid-April lows. * 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond A number of big players in the sector are lagging badly. Here are four healthcare stocks to sell now:InvestorPlace - Stock Market News, Stock Advice & Trading Tips Healthcare Stocks to Sell: Johnson & Johnson (JNJ)Shares of Johnson & Johnson (NYSE:JNJ) are dropping hard, down more than 4% on Friday as I write this and returning to lows not seen since early June. The move cuts below the stock's 200-day moving average and marks an inability to challenge the prior highs from back in December. The company continues to be dogged by legal risks related to baby powder asbestos claims.The company will next report results on July 16 before the bell. Analysts are looking for earnings of $2.42 per share on revenues of $20.4 billion. When the company last reported on April 16, earnings of $2.10 beat estimates by six cents on a 0.1% rise in revenues. Abbott Laboratories (ABT)Abbott Laboratories (NYSE:ABT) shares have fallen below their 20-day moving average for the first time since late May in what looks like the latest pullback within a secular uptrend that has been in play since 2016. Barclays analysts recently highlighted the company's impressive 7.1% organic revenue growth rate but noted very high investor expectations. Some profit taking should be expected. * 10 Stocks Driving the Market to All-Time Highs (And Why) The company will next report results on July 17 before the bell. Analysts are looking for earnings of 80 cents per share on revenues of $8 billion. When the company last reported on April 17, earnings of 63 cents per share beat estimates by a penny on a 2% rise in revenues. Intuitive Surgical (ISRG)Shares of Intuitive Surgical (NASDAQ:ISRG) are threatening to fall back below their 200-day moving average after struggling to reclaim that level after a nasty 22% decline from its mid-April high. This marks a continuation of a sideways range going back to the summer of 2018. The company is a maker of robotic surgical systems.The company will next report results on July 18 after the close. Analysts are looking for earnings of $2.87 per share on revenues of just over $1 billion. When the company last reported on April 18, earnings of $2.61 missed estimates by nine cents on a 14.9% rise in revenues. Illumnia (ILMN)Shares of Illumnia (NASDAQ:ILMN), which provides sequencing solutions for genetic analysis, is suffering a decline of more than 16% in mid-day trading after management guided second-quarter revenues below consensus estimates. Sales growth was impacted by lower than expected contributions from genomics initiatives. Shares were downgraded by analysts at Bank of America Merrill Lynch from buy to sell. Earlier this week, the stock hit an all-time high. * 7 Retail Stocks to Buy for the Second Half of 2019 ISRG stock will next report results on July 29 after the close. Analysts are looking for earnings of $1.42 per share on revenues of $885.6 million. When the company last reported on April 25, earnings of $2.56 beat estimates by 30 cents per share on an 8.2% rise in revenues.As of this writing, William Roth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy for Less Than Book * 7 Marijuana Stocks With Critical Levels to Watch * The 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond The post 4 Healthcare Stocks That Are Feeling Sick  appeared first on InvestorPlace.

  • Bull of the Day: Penumbra (PEN)
    Zacks5 days ago

    Bull of the Day: Penumbra (PEN)

    Bull of the Day: Penumbra (PEN)

  • PR Newswire6 days ago

    Abbott Announces FDA Approval of the Alinity™ s System, the Latest Technology for Screening and Protecting the U.S. Blood and Plasma Supply

    ABBOTT PARK, Ill., July 11, 2019 /PRNewswire/ -- Abbott (ABT) announced today U.S. Food and Drug Administration (FDA) approval for its new blood and plasma screening Alinity™ s System.  This new solution will bring the latest screening technology to U.S. blood and plasma centers. Alinity s is designed to screen blood and plasma more efficiently within a smaller space versus commercially available competitive systems. In a testing specialty that can require extensive hands-on time, the additional automation and flexibility of Alinity s will help blood and plasma centers improve productivity and maintain the highest levels of accuracy. "Alinity s is a significant leap forward when it comes to speed, automation and efficiency for blood and plasma screening," said Louis Morrone, vice president, Transfusion Medicine, Abbott.

  • The 10 Biggest Healthcare Stocks
    Motley Fool7 days ago

    The 10 Biggest Healthcare Stocks

    How big does a company's market cap need to be to make the top 10 list of healthcare stocks? $111 billion.

  • Abbott (ABT) Earnings Expected to Grow: Should You Buy?
    Zacks7 days ago

    Abbott (ABT) Earnings Expected to Grow: Should You Buy?

    Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Analysts bullish on Boston Scientific's plans for 75 new products by 2022
    American City Business Journals14 days ago

    Analysts bullish on Boston Scientific's plans for 75 new products by 2022

    Boston Scientific CEO Michael Mahoney laid out the long-term strategy for the company late last week, including a plan to launch 75 new cardiac valve, brain stimulation and other products by 2022.

  • Is Abbott Laboratories (NYSE:ABT) Investing Your Capital Efficiently?
    Simply Wall St.15 days ago

    Is Abbott Laboratories (NYSE:ABT) Investing Your Capital Efficiently?

    Today we'll look at Abbott Laboratories (NYSE:ABT) and reflect on its potential as an investment. To be precise, we'll...

  • How Citigroup and Other Hedge Fund Favorites Performed in Q2
    Insider Monkey18 days ago

    How Citigroup and Other Hedge Fund Favorites Performed in Q2

    Insider Monkey tracks hedge funds, billionaires, and prominent value investors for a very simple reason: their consensus picks generally outperform the market. We aren’t the only research shop broadcasting this fact using a bullhorn. Here is what strategist Ben Snider said in Goldman Sachs’ periodic hedge fund report: “Despite the strong track record of popular […]